Skip to main content

Table 1 Baseline characteristics of the patients in the two treatment groups

From: The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Characteristics Sorafenib
(n = 56)
Sorafenib + TACE
(n = 48)
Total
(n = 104)
P
Gender
 Male, n (%) 48 (85.71%) 46 (95.83%) 94 (90.38%) 0.103
 Female, n (%) 8 (14.29%) 2(4.17%) 10 (9.62%)
Age (years) 50.23 ± 11.88 47.6 ± 12.73 49.02 ± 12.29 0.279
Antiviral therapy
 Yes, n (%) 25 (44.64%) 27 (56.25%) 52 (50%) 0.238
 No, n (%) 31 (55.36%) 21 (43.75%) 52 (50%)
Positive for HBsAg
 Yes, n (%) 48 (85.71%) 45 (93.75%) 93 (89.42%) 0.184
 No, n (%) 8 (14.29%) 3 (6.25%) 11 (10.58%)
Liver cirrhosis
 Yes, n (%) 45 (80.36%) 32 (66.67%) 77 (74.04%) 0.112
 No, n (%) 11 (19.64%) 16 (33.33%) 27 (25.96%)
PVH
 Yes, n (%) 34 (60.71%) 27 (56.25%) 61 (58.65%) 0.645
 No, n (%) 22 (39.29%) 21 (43.75%) 43 (41.35%)
Ascites
 Yes, n (%) 14 (25%) 8 (16.67%) 22 (21.15%) 0.3
 No, n (%) 42 (75%) 40 (83.33%) 82 (78.85%)
Splenomegaly
 Yes, n (%) 30 (53.57%) 24 (50%) 54 (51.92%) 0.716
 No, n (%) 26 (46.43%) 24 (50%) 50 (48.08%)
Esophageal varix
 None, n (%) 46 (82.14%) 44 (91.67%) 90 (86.54%) 0.220
 Mild, n (%) 7 (12.5%) 2(4.17%) 9 (8.65%)
 Moderate, n (%) 1 (1.79%) 2 (4.17%) 3 (2.88%)
 Severe, n (%) 2 (3.57%) 0 2 (1.92%)
Diabetes
 Yes, n (%) 5 (8.93%) 1 (2.08%) 6 (5.77%) 0.214
 No, n (%) 51 (91.07%) 47(97.92%) 98 (94.23%)
Tumor number 2 (1,4) 2 (1,4) 2 (1,4) 0.169
Tumor diameter (cm) 9.1 (1,19.5) 7.65 (1,19) 8.65 (1,19.5) 0.172
Vascular invasion
 Yes, n (%) 37 (66.07%) 26 (54.17%) 41 (39.42%) 0.216
 No, n (%) 19 (33.93%) 22 (45.83%) 63 (60.58%)
Metastasis, n (%)
 Yes, n (%) 17 (30.36%) 21 (43.75%) 38 (36.54%) 0.157
 No, n (%) 39 (69.64%) 27 (56.25%) 66 (63.46%)
BCLC stage B/C
 B, n (%) 10 (17.86%) 16 (33.33%) 26 (25%) 0.069
 C, n (%) 46 (82.14%) 32 (66.67%) 78 (75%)
Child-Pugh stage A/B
 A, n (%) 45 (80.36%) 46 (95.83%) 91 (87.50%) 0.017
 B, n (%) 11 (19.64%) 2 (4.17%) 13 (12.50%)
TBil (μmol/L) 12.45 (2.9,49.5) 12.5 (5,34.9) 12.45 (2.9,49.5) 0.500
ALT (IU/L) 41.5 (4171) 42.5 (13,199) 42 (4199) 0.469
ALB (g/L) 39.23 ± 4.94 41.44 ± 5.14 40.25 ± 5.13 0.028
PT (s) 13.05 (10.9,53) 12.7 (10.4,16.4) 12.85 (10.4,53) 0.090
AFP (ng/mL) 400 (0.78, 12,100) 172.5 (1.4, 4000) 350 (0.78, 12,100) 0.203
  < 400 ng/mL, n (%) 23 (48.94%) 33 (58.93%) 56 (54.37%)  
  ≥ 400 ng/mL, n (%) 24 (51.06%) 23 (41.07%) 47 (45.63%)  
PVTT, n (%)
 I 11 (19.64%) 5 (10.42%) 16 (15.38%) 0.254
 II 10 (17.86%) 13 (22.12%) 23 (22.12%)
 III 8 (14.29%) 6 (12.5%) 14 (13.46%)
 IV 3 (5.36%) 0 3 (2.88%)
  1. AFP α-fetoprotein, ALB albumin, ALT alanine aminotransferase, BCLC Barcelona Clinic Liver Cancer, HBsAg hepatitis B virus surface antigen, HCC hepatocellular carcinoma, PLT platelet count, PT prothrombin time, PVH portal vein hypertension, TBil total bilirubin. Values are shown as mean ± standard deviation, n (%) or median (range)